Pfizer is paying $47.50 a share in cash for Metsera, a 43% premium on the startup’s closing price on Friday that gives the ...

Pfizer is doubling down on obesity treatments by spending 4.9 billion US dollars (£3.6 billion) on the development-stage drugmaker Metsera. The Covid-19 vaccine and treatment maker said on Monday that ...

A few years ago, Pfizer (NYSE: PFE) saw revenue soar to record heights thanks to coronavirus-related sales, from its vaccine ...

Pfizer's (PFE) short interest as a percent of float has fallen 9.0% since its last report. According to exchange reported data, there are now 103.47 million shares sold short, which is 1.82% of all ...

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will ...

Wachtell guides Pfizer as it scrambles to win a slice in booming obesity drug market with Paul Weiss-repped Metsera ...

A two-day federal vaccine advisory meeting crammed with chaos, confusion, inept debate, bizarre comments, and a hot mic ...

In remarks in Providence, Rhode Island, Powell noted that there are risks to both of the Fed’s goals of seeking maximum ...

At first, Ethel Branch thought her two-year-old son, Patro, had a cold or maybe the flu. Frantic, Branch rushed Patro to the ...

This page may contain affiliate links to legal sports betting partners. If you sign up or place a wager, FOX Sports may be compensated. Read more about Sports Betting on FOX Sports. Football fans, ...

Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates ...